TCG CROSSOVER MANAGEMENT LLC
Q1 2022 Form 13-F

PALO ALTO, CALIFORNIA
CIK 0001839948 · CRD 311718 · SEC-registered investment adviser
$249.1M Reported Value Total

TCG CROSSOVER MANAGEMENT, LLC reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $880,078,419, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
3 funds · $3.8B gross asset value
Other: $3.8B
Source: Form ADV filed 2026-05-29
Reported value
$249.1M
Quarter over quarter
-11.0%
Holdings
20
Top-10 concentration
78.8%

Key People

Form ADV owners & control persons
Chen Ming Yu
MANAGING PARTNER
Craig David Skaling
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2022 13F record

Q1 2022 13F filing summary

Q1 2022 Form 13F portfolio summary
Period of report March 31, 2022
Filed May 16, 2022
Form 13F-HR
Reported value $249.1M
Positions 20
Change in reported value +16.6%
New positions 5
Exited positions 0
Position turnover 25.0%
Top-10 concentration 78.8%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
57 $3.5B
Q2 2026 13F
Filed Aug 14, 2026
54 $4.2B
Q1 2026 13F
Filed May 15, 2026
49 $3.5B
Q4 2025 13F
Filed Feb 17, 2026
43 $3.0B
Q3 2025 13F
Filed Nov 17, 2025
40 $2.0B
Q2 2025 13F
Filed Aug 14, 2025
37 $875.5M
Q1 2025 13F
Filed May 14, 2025
37 $733.1M
Q4 2024 13F
Filed Feb 14, 2025
38 $1.0B
Q3 2024 13F
Filed Nov 14, 2024
36 $1.2B
Q2 2024 13F
Filed Aug 14, 2024
32 $959.5M
Q1 2024 13F
Filed May 15, 2024
33 $1.3B
Q4 2023 13F
Filed Feb 14, 2024
29 $901.7M
Q3 2023 13F
Filed Nov 14, 2023
26 $679.1M
Q2 2023 13F
Filed Aug 14, 2023
22 $609.8M
Q1 2023 13F
Filed May 15, 2023
22 $513.0M
Q4 2022 13F
Filed Feb 14, 2023
21 $566.6M
Q3 2022 13F
Filed Nov 14, 2022
21 $333.4M
Q2 2022 13F
Filed Aug 15, 2022
22 $235.4M
Q1 2022 13F
Filed May 16, 2022
20 $249.1M
Q4 2021 13F
Filed Feb 18, 2022
15 $213.6M

Top 20 holdings · Q1 2022

Largest Q1 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 ISEE Iveric Bio, Inc. $42.4M 17.01%
2 VRDN Viridian Therapeutics Inc $24.3M 9.75%
3 COGT Cogent Biosciences, Inc. $22.3M 8.96%
4 ACRS Aclaris Therapeuitics, Inc. $19.7M 7.92%
5 GERN Geron Corporation $19.4M 7.8%
6 CBAY CymaBay Therapeutics, Inc. $18.4M 7.37%
7 AVTE Aerovate Therapeutics, Inc. $16.3M 6.55%
8 KDNY Chinook Therapeutics, Inc. $14.4M 5.79%
9 TYRA Tyra Biosciences, Inc. $9.6M 3.85%
10 TNGX Tango Therapeutics, Inc. $9.5M 3.82%
11 ALPN Alpine Immune Sciences, Inc. $9.3M 3.72%
12 KURA Kura Oncology, Inc. $8.1M 3.27%
13 MRUS Merus N.V. $7.9M 3.18%
14 AKUS Akouos, Inc. $6.4M 2.57%
15 DNTH Magenta Therapeutics, Inc. $6.2M 2.47%
16 TRDA Entrada Therapeutics, Inc. $6.1M 2.46%
17 ZLAB Zai Lab LTD-ADR $4.2M 1.68%
18 PRDS Pardes Biosciences, Inc. $1.7M 0.66%
19 ANAB AnaptysBio, Inc. $1.4M 0.58%
20 ELEV Elevation Oncology, Inc. $1.4M 0.56%

Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings